Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185759 | 0.84 | HCAR2 (0.57) | CHRNA4PSMB8MMECYP1A2SMPD1 | |
| SCHEMBL2637696 | 0.82 | CHRNA4 (0.49) | CHRNA4PSMB8MMESMPD1HCAR2 | |
| SCHEMBL1190827 | 0.82 | CHRNA4 (0.50) | CHRNA4PSMB8MMECYP1A2SMPD1 | |
| Hydrochloric Acid SCHEMBL2948313 | 0.82 | HCAR2 (0.55) | CHRNA4PSMB8MMECYP1A2SMPD1 | |
| SCHEMBL1536321 | 0.82 | CHRNA4 (0.52) | CHRNA4PSMB8MMECYP1A2SMPD1 | |
| SCHEMBL12674209 | 0.79 | CHRNA4 (0.47) | CHRNA4PSMB8MMECYP1A2SMPD1 | |
| SCHEMBL17263376 | 0.79 | SMPD1 (0.49) | CHRNA4SMPD1HCAR2ALDH1A1NPC1 | |
| SCHEMBL12835947 | 0.79 | SMN1; SMN2 (0.51) | CHRNA4PSMB8MMECYP1A2SMPD1 | |
| SCHEMBL15004534 | 0.79 | CHRNA4 (0.47) | CHRNA4PSMB8MMECYP1A2SMPD1 | |
| SCHEMBL13543698 | 0.79 | CHRNA4 (0.47) | CHRNA4PSMB8MMECYP1A2SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| EP-3810595-A1 | OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112334462-A | OGA inhibitor compounds | 詹森药业有限公司 | 2021-02-05 | — | — | CN | disclosed |
| EP-2480247-B1 | NOVEL NPR-B AGONISTS | SHIRE ORPHAN THERAPIES GMBH (DE) | 2020-02-12 | — | — | EP | disclosed |
| WO-2019243531-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| US-9822147-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-20170313743-A1 | NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-9745344-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-13 | — | — | US | disclosed |
| US-20160194357-A1 | Novel NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-07 | — | — | US | disclosed |
| EP-0190298-B1 | 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACIDS AND DERIVATIVES THEREOF | ZAMBON S.p.A. (IT) | 1989-10-18 | — | — | EP | disclosed |
| US-4772719-A | FROM DIHALOFORMALDOXIME AND ALKYNE, CYCLIZATION | ZAMBON S.P.A. (IT) | 1988-09-20 | — | — | US | disclosed |
| US-4766137-A | 4-(isoxazolyl)-thiazole-2-oxamic acids and derivatives thereof | ZAMBON S.P.A. (IT) | 1988-08-23 | — | — | US | disclosed |
| US-4766138-A | Use of 4-(isoxazolyl)-thiazole-2-oxamic acid derivatives | ZAMBON S.P.A. (IT) | 1988-08-23 | — | — | US | disclosed |
| EP-0207955-A1 | PROCESS FOR THE PREPARATION OF 3,5-DISUBSTITUTED ISOXAZOLES. | ZAMBON SPA (IT) | 1987-01-14 | — | — | EP | disclosed |
| EP-0191045-A1 | USE OF 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACID DERIVATIVES. | ZAMBON SPA (IT) | 1986-08-20 | — | — | EP | disclosed |
| EP-0190298-A1 | 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACIDS AND DERIVATIVES THEREOF. | ZAMBON SPA (IT) | 1986-08-13 | — | — | EP | disclosed |
| WO-1986003490-A1 | PROCESS FOR THE PREPARATION OF 3,5-DISUBSTITUTED ISOXAZOLES | ZAMBON S.P.A. (IT) | 1986-06-19 | — | — | WO | disclosed |
| WO-1986000900-A1 | 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACIDS AND DERIVATIVES THEREOF | ZAMBON, S.P.A. (IT) | 1986-02-13 | — | — | WO | disclosed |
| WO-1986000899-A1 | USE OF 4-(ISOXAZOLYL)-THIAZOLE-2-OXAMIC ACID DERIVATIVES | ZAMBON S.P.A. (IT) | 1986-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313743-A1 | NPR-B Agonists | NPR1, NPR3, NPBWR1 | CHRNA4 196/4885PSMB8 1015/4885MME 1069/4885 |
| US-20160194357-A1 | Novel NPR-B Agonists | NPR1, NPR3, NPBWR1 | CHRNA4 217/4885PSMB8 1141/4885MME 1125/4885 |
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | CHRNA4 1809/4885PSMB8 380/4885MME 621/4885 |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | NPR1, EDNRB, NPR3 | CHRNA4 371/4885PSMB8 1420/4885MME 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.